Results 1 to 10 of about 1,044,515 (400)

A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand [PDF]

Human Vaccines & Immunotherapeutics, 2019
Being vigilant of the potential for an influenza pandemic, the Global Action Plan for Influenza Vaccines (GAP) promoted the establishment and maintenance of local vaccine manufacturing capacity.
Punnee Pitisuttithum, Ponthip Wirachwong
doaj   +2 more sources

Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. [PDF]

, 2013
BackgroundLittle is known on the effectiveness of influenza vaccine in ESRD patients. This study compared the incidence of hospitalization, morbidity, and mortality in end-stage renal disease (ESRD) patients undergoing hemodialysis (HD) between cohorts ...
Chang, Chiz-Tzung, Huang, Chiu-Ching, Liang, Chih-Chia, Lin, Cheng-Li, Lin, Po-Chang, Liu, Yao-Lung, Morisky, Donald E, Sung, Fung-Chang, Wang, I-Kuan, Yen, Tzung-Hai   +9 more
core   +9 more sources

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Nature Medicine, 2022
Currently, licensed seasonal influenza vaccines display variable vaccine effectiveness, and there remains a need for novel vaccine platforms capable of inducing broader responses against viral protein domains conserved among influenza subtypes.
Katherine V. Houser, Grace L. Chen, Cristina A Carter, M. Crank, Thuy A. Nguyen, Maria C. Burgos Florez, N. Berkowitz, Floreliz H. Mendoza, C. S. Hendel, Ingelise J. Gordon, Emily E. Coates, Sandra Vazquez, Judy A. Stein, Christopher L. Case, H. Lawlor, Kevin Carlton, M. Gaudinski, L. Strom, A. Hofstetter, C. Liang, S. Narpala, C. Hatcher, Rebecca A. Gillespie, A. Creanga, M. Kanekiyo, J. Raab, Sarah F. Andrews, Yi Zhang, E. Yang, Lingshu Wang, K. Leung, W. Kong, Alec W. Freyn, Raffael Nachbagauer, P. Palese, R. Bailer, A. McDermott, R. Koup, J. Gall, F. Arnold, J. Mascola, B. Graham, J. Ledgerwood, Joseph Lasonji Abidemi O. Pamela Jennifer Brenda Laura Ja Casazza Holman Ola Costner Cunningham Larkin Novik, J. Casazza, L. Holman, Abidemi O. Ola, Pamela J M Costner, Jennifer Cunningham, B. Larkin, L. Novik, J. Saunders, W. Whalen, Xiaolin Wang, A. Eshun, Alison Taylor, K. Cheng, C. Laurencot, J. Cox, S. Sitar, L. Le, Iris Pittman, O. Vasilenko, R. S. Rothwell, G. Yamshchikov, Eugenia Burch, S. Hickman, Olga Trofymenko, Catina Boyd, Preeti Apte, C. T. Cartagena, Renunda Hicks, Pernell Williams, Zana Blaku, Colin Tran   +74 more
semanticscholar   +1 more source

The Role of Psychological Factors and Vaccine Conspiracy Beliefs in Influenza Vaccine Hesitancy and Uptake among Jordanian Healthcare Workers during the COVID-19 Pandemic

Vaccines, 2022
Vaccination to prevent influenza virus infection and to lessen its severity is recommended among healthcare workers (HCWs). Health professionals have a higher risk of exposure to viruses and could transmit the influenza virus to vulnerable patients who ...
Malik Sallam, R. Ghazy, Khaled Al-Salahat, Kholoud Al-Mahzoum, Nadin Mohammad AlHadidi, H. Eid, Nariman Kareem, Eyad Al-Ajlouni, Rawan Batarseh, N. Ababneh, Mohammed Sallam, Mariam Alsanafi, Srikanth Umakanthan, Ala’a B. Al-Tammemi, F. Bakri, H. Harapan, A. Mahafzah, Salah T. Al Awaidy   +17 more
semanticscholar   +1 more source

Progress towards the Development of a Universal Influenza Vaccine

Viruses, 2022
Influenza viruses are responsible for millions of cases globally and significantly threaten public health. Since pandemic and zoonotic influenza viruses have emerged in the last 20 years and some of the viruses have resulted in high mortality in humans ...
Wen-Chien Wang, Ekramy E. Sayedahmed, S. Sambhara, S. Mittal   +3 more
semanticscholar   +1 more source

Successful Treatment of Complicated Influenza A(H3N2) Virus Infection and Rhabdomyolysis with Compassionate Use of IV Zanamivir

Pharmaceuticals, 2023
In 2019, EMA licensed intravenous (IV) zanamivir for severe influenza virus infection in children over 6 months as well as adults. Prior to that, it was possible via a compassionate use program.
Maren Alchikh, Patrick E. Obermeier, Brunhilde Schweiger, Barbara A. Rath   +3 more
doaj   +1 more source

Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta‐Analysis

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Influenza infection causes considerable morbidity and mortality in patients with cardiovascular disease. We assessed the effects of the influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease. Methods
Siva H. Yedlapati, Safi U. Khan, S. Talluri, A. Lone, M. Khan, M. Khan, A. Navar, M. Gulati, H. Johnson, S. Baum, E. Michos   +10 more
semanticscholar   +1 more source

Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors

medRxiv, 2021
Background: The test-negative design is commonly used to estimate influenza and COVID-19 vaccine effectiveness (VE). In these studies, correlated COVID-19 and influenza vaccine behaviors may introduce a confounding bias where controls are included with ...
M. Doll, S. Pettigrew, Julia Ma, Aman Verma   +3 more
semanticscholar   +1 more source

Influenza and Influenza Vaccine: A Review

Journal of midwifery & women's health, 2021
Influenza is a highly contagious, deadly virus, killing nearly half a million people yearly worldwide. The classic symptoms of influenza are fever, fatigue, cough, and body aches.
Cynthia Nypaver, Cynthia Dehlinger, Chelsea Carter   +2 more
semanticscholar   +1 more source

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis

Influenza and Other Respiratory Viruses, 2021
Standard‐dose seasonal influenza vaccines often produce modest immunogenic responses in adults ≥65 years old. MF59 is intended to elicit a greater magnitude and increased breadth of immune response.
B. Coleman, R. Sanderson, Mendel D M Haag, Ian McGovern   +3 more
semanticscholar   +1 more source